Success Metrics

Clinical Success Rate
95.2%

Based on 20 completed trials

Completion Rate
95%(20/21)
Active Trials
0(0%)
Results Posted
70%(14 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_3
8
38%
Ph not_applicable
1
5%
Ph phase_4
5
24%
Ph phase_2
5
24%

Phase Distribution

0

Early Stage

5

Mid Stage

13

Late Stage

Phase Distribution19 total trials
Phase 2Efficacy & side effects
5(26.3%)
Phase 3Large-scale testing
8(42.1%)
Phase 4Post-market surveillance
5(26.3%)
N/ANon-phased studies
1(5.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.2%

20 of 21 finished

Non-Completion Rate

4.8%

1 ended early

Currently Active

0

trials recruiting

Total Trials

21

all time

Status Distribution
Completed(20)
Terminated(1)

Detailed Status

Completed20
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
0
Success Rate
95.2%
Most Advanced
Phase 4

Trials by Phase

Phase 25 (26.3%)
Phase 38 (42.1%)
Phase 45 (26.3%)
N/A1 (5.3%)

Trials by Status

completed2095%
terminated15%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT00624819Phase 3

Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine

Completed
NCT00463437Phase 3

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Completed
NCT00652951Phase 3

Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib

Completed
NCT00370396Phase 3

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Completed
NCT01003418Phase 2

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Terminated
NCT00344318Phase 3

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Completed
NCT00586612Phase 3

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

Completed
NCT00127855Phase 2

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Completed
NCT00134719Phase 2

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Completed
NCT00680914Phase 3

Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™

Completed
NCT00871338Phase 2

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

Completed
NCT00657709Phase 3

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Completed
NCT01193582Phase 4

A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria

Completed
NCT00836641Phase 4

Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics

Completed
NCT00294294Phase 4

Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa

Completed
NCT01263210Not Applicable

Pneumococcal Vaccination of Otitis-prone Children

Completed
NCT00195611

Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media

Completed
NCT00679159Phase 2

A Study of MVA85A in Healthy Children and Infants

Completed
NCT00276107Phase 4

Study Evaluating Prevenar Vaccine in Healthy Infants

Completed
NCT00195390

Study Investigating Administration of Prevenar for Post-Marketing Surveillance

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
21